FDA’s Metric System: Quality Scores Are High Priority For Agency, But Industry Concerns Keep Pace Slow
This article was originally published in RPM Report
Executive Summary
FDA is taking the next step towards gathering and reporting manufacturing quality metrics data by releasing a draft guidance outlining an initial list of proposed metrics. However, FDA made clear during an August feedback meeting that it isn’t going to rush the changes through.
You may also be interested in...
FDA’s Call for Quality: Revamped GMP Initiative Stresses Cost Savings
FDA is kicking off phase two of its 21st Century GMP initiative using new authorities and funding under the FDA Safety & Innovation Act. To encourage investment in quality manufacturing systems, the agency is highlighting the cost savings seen by early adopters of quality systems. And if that’s not incentive enough, FDA has already shown it is quite willing to use the new enforcement authorities. Ranbaxy is a case in point.
FDA Quality Profiling: Agency Hopes to Channel Corporate Attention (And Money) To Quality Systems
FDA’s drug compliance leadership sees new risk assessment authority for setting inspection schedules from FDASIA as an appealing foundation for collecting and preparing profiles of drug manufacturers. Just don’t call them “report cards.”
Medicare Reaffirms Faith In Formulary Review Process Ahead Of Part D Changes
Dramatic transformation in the US Medicare Part D benefit design does not require any changes to CMS’ overall approach to reviewing formulary submissions from private drug plan sponsors, the agency says in its final guidance implementing the design changes for 2025.